Beranda › Glioma › Nebraska › Omaha
Uji klinis Glioma di Omaha, NE
5 studi untuk Glioma mencari peserta di lokasi sekitar Omaha (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
Menerima pesertaFase 1/2
- Children's Hospital and Medical Center of Omaha, Omaha
- University of Nebraska Medical Center, Omaha
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
Menerima pesertaFase 2
- University of Nebraska Medical Center, Omaha
A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
Menerima pesertaFase 1
- University of Nebraska Medical Center, Omaha
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Menerima pesertaFase 2
- Nebraska Cancer Specialists - Midwest Cancer Center - Legacy, Omaha
A Study Utilizing Escitalopram in Glioma Patients
Menerima pesertaFase 2
- University of Nebraska Medical Center, Omaha
Uji klinis Glioma di kota lain
- New York City, NY25 studi
- Houston, TX23 studi
- Boston, MA20 studi
- Washington, DC19 studi
- Philadelphia, PA16 studi
- Columbus, OH15 studi
- Miami, FL15 studi
- San Francisco, CA14 studi
- Chicago, IL13 studi
- Durham, NC12 studi
- Seattle, WA11 studi
- St. Louis, MO10 studi
Studi lain di Omaha
- Kanker Prostat27 studi
- Kanker Paru Non-Sel Kecil24 studi
- Kanker Payudara22 studi
- Kanker (semua jenis)18 studi
- Kanker Kolorektal18 studi
- Mieloma Multipel16 studi
- Kanker Ovarium14 studi
- Limfoma Non-Hodgkin14 studi
- Kanker Pankreas14 studi
- Kanker Metastatik13 studi
- Karsinoma Sel Skuamosa Kepala dan Leher13 studi
- Gagal Jantung13 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.